Cargando…

Pharmacokinetic and pharmacodynamic properties of pantoprazole in calves

INTRODUCTION: Development of abomasal ulceration is a large concern, especially within calves; however, there is a paucity of research into the use of gastro protectants in ruminant species. Proton pump inhibitors, such as pantoprazole, are widely used in humans and companion animals. Their efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Olivarez, Jeff D., Mulon, Pierre-Yves, Ebner, Lisa S., Cremerius, Haley, Cantrell, Channing, Rahn, Rebecca, Soto-Gonzalez, Windy, Bergman, Joan, Cox, Sherry, Mochel, Jonathan P., Kreuder, Amanda J., Smith, Joe S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9923100/
https://www.ncbi.nlm.nih.gov/pubmed/36794231
http://dx.doi.org/10.3389/fvets.2022.1101461
_version_ 1784887668308443136
author Olivarez, Jeff D.
Mulon, Pierre-Yves
Ebner, Lisa S.
Cremerius, Haley
Cantrell, Channing
Rahn, Rebecca
Soto-Gonzalez, Windy
Bergman, Joan
Cox, Sherry
Mochel, Jonathan P.
Kreuder, Amanda J.
Smith, Joe S.
author_facet Olivarez, Jeff D.
Mulon, Pierre-Yves
Ebner, Lisa S.
Cremerius, Haley
Cantrell, Channing
Rahn, Rebecca
Soto-Gonzalez, Windy
Bergman, Joan
Cox, Sherry
Mochel, Jonathan P.
Kreuder, Amanda J.
Smith, Joe S.
author_sort Olivarez, Jeff D.
collection PubMed
description INTRODUCTION: Development of abomasal ulceration is a large concern, especially within calves; however, there is a paucity of research into the use of gastro protectants in ruminant species. Proton pump inhibitors, such as pantoprazole, are widely used in humans and companion animals. Their efficacy in ruminant species is undetermined. The objectives of this study were to 1) estimate the plasma pharmacokinetic parameters for pantoprazole in neonatal calves after three days of intravenous (IV) or subcutaneous (SC) administration, and 2) measure the effect pantoprazole had on abomasal pH over the treatment period. METHODS: Pantoprazole was administered to 6 Holstein-Angus cross bull calves at a dose of 1 mg/kg (IV) or 2 mg/kg (SC), once a day (every 24 h) for three days. Plasma samples were collected over a 72 h period and analyzed via HPLC-UV for determining pantoprazole concentrations. Pharmacokinetic parameters were derived via non-compartmental analysis. Abomasal (n= 8) samples were collected via abomasal cannulas over a 12 h period, per calf per day. Abomasal pH was determined via a bench top pH analyzer. RESULTS: Following Day 1 of IV administration, plasma clearance, elimination half-life, and volume of distribution of pantoprazole were estimated at 199.9 mL/kg/h, 1.44 h, and 0.51 L/kg, respectively. On Day 3 of IV administration, the reported values were 192.9 mL/kg/h, 2.52 h, and 1.80 L/kg mL, respectively. Elimination half-life and volume of distribution (V/F) of pantoprazole following SC administration were estimated at 1.81 h and 0.55 L/kg, respectively, on Day 1; and 2.99 h and 2.82 L/kg, respectively, on Day 3. DISCUSSION: The reported values for IV administration were similar to those previously reported in calves. SC administration appears to be well absorbed and tolerated. The sulfone metabolite was detectable for 36 h after the last administration for both routes. Abomasal pH was significantly higher than the pre-pantoprazole pH 4, 6, and 8 h after administration in both the IV and SC groups. Further studies of pantoprazole as a treatment/preventative for abomasal ulcers are warranted.
format Online
Article
Text
id pubmed-9923100
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99231002023-02-14 Pharmacokinetic and pharmacodynamic properties of pantoprazole in calves Olivarez, Jeff D. Mulon, Pierre-Yves Ebner, Lisa S. Cremerius, Haley Cantrell, Channing Rahn, Rebecca Soto-Gonzalez, Windy Bergman, Joan Cox, Sherry Mochel, Jonathan P. Kreuder, Amanda J. Smith, Joe S. Front Vet Sci Veterinary Science INTRODUCTION: Development of abomasal ulceration is a large concern, especially within calves; however, there is a paucity of research into the use of gastro protectants in ruminant species. Proton pump inhibitors, such as pantoprazole, are widely used in humans and companion animals. Their efficacy in ruminant species is undetermined. The objectives of this study were to 1) estimate the plasma pharmacokinetic parameters for pantoprazole in neonatal calves after three days of intravenous (IV) or subcutaneous (SC) administration, and 2) measure the effect pantoprazole had on abomasal pH over the treatment period. METHODS: Pantoprazole was administered to 6 Holstein-Angus cross bull calves at a dose of 1 mg/kg (IV) or 2 mg/kg (SC), once a day (every 24 h) for three days. Plasma samples were collected over a 72 h period and analyzed via HPLC-UV for determining pantoprazole concentrations. Pharmacokinetic parameters were derived via non-compartmental analysis. Abomasal (n= 8) samples were collected via abomasal cannulas over a 12 h period, per calf per day. Abomasal pH was determined via a bench top pH analyzer. RESULTS: Following Day 1 of IV administration, plasma clearance, elimination half-life, and volume of distribution of pantoprazole were estimated at 199.9 mL/kg/h, 1.44 h, and 0.51 L/kg, respectively. On Day 3 of IV administration, the reported values were 192.9 mL/kg/h, 2.52 h, and 1.80 L/kg mL, respectively. Elimination half-life and volume of distribution (V/F) of pantoprazole following SC administration were estimated at 1.81 h and 0.55 L/kg, respectively, on Day 1; and 2.99 h and 2.82 L/kg, respectively, on Day 3. DISCUSSION: The reported values for IV administration were similar to those previously reported in calves. SC administration appears to be well absorbed and tolerated. The sulfone metabolite was detectable for 36 h after the last administration for both routes. Abomasal pH was significantly higher than the pre-pantoprazole pH 4, 6, and 8 h after administration in both the IV and SC groups. Further studies of pantoprazole as a treatment/preventative for abomasal ulcers are warranted. Frontiers Media S.A. 2023-01-30 /pmc/articles/PMC9923100/ /pubmed/36794231 http://dx.doi.org/10.3389/fvets.2022.1101461 Text en Copyright © 2023 Olivarez, Mulon, Ebner, Cremerius, Cantrell, Rahn, Soto-Gonzalez, Bergman, Cox, Mochel, Kreuder and Smith. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Veterinary Science
Olivarez, Jeff D.
Mulon, Pierre-Yves
Ebner, Lisa S.
Cremerius, Haley
Cantrell, Channing
Rahn, Rebecca
Soto-Gonzalez, Windy
Bergman, Joan
Cox, Sherry
Mochel, Jonathan P.
Kreuder, Amanda J.
Smith, Joe S.
Pharmacokinetic and pharmacodynamic properties of pantoprazole in calves
title Pharmacokinetic and pharmacodynamic properties of pantoprazole in calves
title_full Pharmacokinetic and pharmacodynamic properties of pantoprazole in calves
title_fullStr Pharmacokinetic and pharmacodynamic properties of pantoprazole in calves
title_full_unstemmed Pharmacokinetic and pharmacodynamic properties of pantoprazole in calves
title_short Pharmacokinetic and pharmacodynamic properties of pantoprazole in calves
title_sort pharmacokinetic and pharmacodynamic properties of pantoprazole in calves
topic Veterinary Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9923100/
https://www.ncbi.nlm.nih.gov/pubmed/36794231
http://dx.doi.org/10.3389/fvets.2022.1101461
work_keys_str_mv AT olivarezjeffd pharmacokineticandpharmacodynamicpropertiesofpantoprazoleincalves
AT mulonpierreyves pharmacokineticandpharmacodynamicpropertiesofpantoprazoleincalves
AT ebnerlisas pharmacokineticandpharmacodynamicpropertiesofpantoprazoleincalves
AT cremeriushaley pharmacokineticandpharmacodynamicpropertiesofpantoprazoleincalves
AT cantrellchanning pharmacokineticandpharmacodynamicpropertiesofpantoprazoleincalves
AT rahnrebecca pharmacokineticandpharmacodynamicpropertiesofpantoprazoleincalves
AT sotogonzalezwindy pharmacokineticandpharmacodynamicpropertiesofpantoprazoleincalves
AT bergmanjoan pharmacokineticandpharmacodynamicpropertiesofpantoprazoleincalves
AT coxsherry pharmacokineticandpharmacodynamicpropertiesofpantoprazoleincalves
AT mocheljonathanp pharmacokineticandpharmacodynamicpropertiesofpantoprazoleincalves
AT kreuderamandaj pharmacokineticandpharmacodynamicpropertiesofpantoprazoleincalves
AT smithjoes pharmacokineticandpharmacodynamicpropertiesofpantoprazoleincalves